Senores Pharmaceuticals' audit record is clean on its face: unqualified opinions in both FY2024-25 and FY2025-26, and no defaults or wilful-defaulter status in its own filings. But the cash conversion of reported profit is weak, IPO proceeds were redirected after the fact, and the group's profit is generated almost entirely inside subsidiaries the group auditor did not itself examine.
Key findings
- Reported profit has not converted into operating cash over five years, while IPO proceeds were redirected
Major- Cumulative operating cash flow was ₹-21 crore against cumulative PAT of ₹222 crore (less other income of ₹73 crore) over the five years through FY2026. Of the ₹107.00 crore IPO proceeds earmarked for the Atlanta sterile injectables facility, only ₹6.98 crore was utilized as of March 31, 2026. The change of object was approved on August 4, 2026, with 99.9991% shareholder approval, but only after the fact. - Audit opinions are clean, but the FY2025-26 CARO report flags a fund mismatch and FY25 carried a remuneration qualification
Major- The standalone audit opinion for FY2025-26 was unqualified, dated 14-05-2026. The CARO report for the same year states ₹184.77 crore of short-term funds were used for long-term purposes. The FY2024-25 report carried a Section 197(16) qualification that executive-director remuneration exceeded statutory limits, resolved by FY2025-26. - Group auditor relied on other auditors for subsidiaries generating 86% of profit
Major- Consolidated PAT was ₹131 crore versus standalone PAT of ₹18.59 crore, meaning 86% of profit sits at subsidiaries. The FY26 consolidated report states the opinion on a subsidiary with ₹1,297.26 crore of assets and ₹102.91 crore of PAT is based solely on that subsidiary's independent auditor's report. In FY25, the auditor did not audit 3 subsidiaries and 1 step-down subsidiary with ₹793.78 crore of assets. - Related-party loans and guarantees to subsidiaries have scaled sharply, with public institutions voting against
Major- Outstanding related-party loans reached ₹360.98 crore and guarantees ₹197.66 crore at FY2025-26 year-end. Public institutional shareholders voted 21.04% against the Ratnatris RPT resolution and 65.79% against the Section 185 limit enhancement. The auditor notes loans were granted repayable on demand or without specified terms. - Promoter remuneration rose 87% in a year while promoter entities pledged shares and a warrant issue passed over dissent
Major- Consolidated KMP remuneration rose from ₹5.59 crore in FY2025 to ₹10.45 crore in FY2026. Promoter pledge rose from 0.00% one year ago to 2.81% in the latest period. The preferential warrant issue passed with 96.45% of votes in favour, but public institutions voted 25.21% against. - Reported profit is shaped by accounting policy choices and one-off items
Major- Consolidated deferred tax swung from a ₹35.44 crore asset as at March 31, 2025 to a ₹40.26 crore charge as at March 31, 2026. Depreciation on acquired tangible assets is charged on WDV basis per a Chartered Engineer's opinion, while subsidiaries use SLM. The CFO attributed a sequential PAT decline to a prior-year foreign exchange fluctuation of ₹14-15 crore, which was "zero practically" in the latest quarter. - Revenue recognition is the auditor's sole recurring KAM while receivables balloon
Major- Revenue recognition was the only Key Audit Matter in FY2024-25 and remained the most significant audit matter in FY2025-26. Consolidated trade receivables rose from ₹124.05 crore to ₹325.22 crore, while the provision for expected credit loss increased only from ₹0.16 crore to ₹0.40 crore. No external customer accounted for 10% or more of group revenue in FY2025, but such details were disclosed for FY2026.
What to watch
- IPO proceeds reallocation. Utilization of the remaining ₹100.02 crore of IPO proceeds, following the August 4, 2026 shareholder approval of the change in objects.
- Warrant conversion. Conversion of the 11,70,000 convertible warrants allotted on March 28, 2026, with the balance ₹71.25 crore receivable by September 28, 2027.
- Apnar Pharma acquisition. Completion of the remaining 25% acquisition, expected during Q2 2026-27.
- IRS penalty contest. Outcome of SPI's contest of the IRS penalty and interest, pending as of the FY2025-26 Annual Report.
- GST appeal. Outcome of the company's appeal against the December 26, 2025 GST demand order, pending as of the FY2025-26 Annual Report.
Bottom line: This is a disclosed and audited record with no defaults and clean opinions. The risk sits in the gap between reported profit and cash, the concentration of profit in unaudited subsidiaries, and the scale of related-party financing. Watch whether the redirected IPO proceeds find productive use, whether the warrants convert, and how the pending tax and regulatory contests resolve.